Allspring Global Investments Holdings LLC Sells 10,462 Shares of Masimo Corporation (NASDAQ:MASI)

Allspring Global Investments Holdings LLC reduced its position in Masimo Corporation (NASDAQ:MASI - Free Report) by 21.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 38,302 shares of the medical equipment provider's stock after selling 10,462 shares during the period. Allspring Global Investments Holdings LLC owned 0.07% of Masimo worth $6,420,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MASI. Smartleaf Asset Management LLC raised its stake in Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 60 shares during the period. Jones Financial Companies Lllp purchased a new stake in shares of Masimo in the fourth quarter worth about $27,000. SBI Securities Co. Ltd. purchased a new position in Masimo during the fourth quarter valued at approximately $46,000. Charles Schwab Investment Management Inc. grew its stake in Masimo by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 377,836 shares of the medical equipment provider's stock valued at $62,456,000 after acquiring an additional 7,808 shares in the last quarter. Finally, Atria Investments Inc purchased a new position in Masimo during the fourth quarter valued at approximately $335,000. 85.96% of the stock is currently owned by institutional investors.

Masimo Trading Down 1.2%

Shares of MASI traded down $2.08 during mid-day trading on Monday, reaching $165.50. The company's stock had a trading volume of 225,907 shares, compared to its average volume of 637,675. The stock has a market cap of $8.97 billion, a PE ratio of -18.12 and a beta of 1.19. The company has a current ratio of 2.17, a quick ratio of 1.62 and a debt-to-equity ratio of 0.67. Masimo Corporation has a 52 week low of $101.61 and a 52 week high of $194.88. The company's fifty day moving average price is $161.89 and its two-hundred day moving average price is $166.46.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.24 by $0.12. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. The company had revenue of $372.00 million during the quarter, compared to analyst estimates of $367.79 million. During the same period in the prior year, the business posted $0.77 EPS. The firm's revenue was down 24.5% compared to the same quarter last year. On average, analysts predict that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of the company's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the transaction, the chief operating officer directly owned 24,172 shares in the company, valued at approximately $3,946,804.16. This represents a 29.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 16.90% of the company's stock.

Analysts Set New Price Targets

MASI has been the subject of several recent analyst reports. Raymond James Financial reduced their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen cut shares of Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Thursday, April 10th. BTIG Research set a $193.00 price target on shares of Masimo and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company cut their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Masimo has a consensus rating of "Moderate Buy" and a consensus target price of $191.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.